Table 1 RA cohort demographics and clinical characteristics.

DAS28-CRP, disease activity score 28-joint count–C-reactive protein; CDAI, clinical disease activity index; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; ACPA, anti–citrullinated peptide antibodies; DMARDs, disease-modifying antirheumatic drugs.

PlaceboVIB4920 (75 mg)VIB4920 (500 mg)VIB4920 (1000 mg)VIB4920 (1500 mg)VIB4920 (total)
n15810121242
Age, mean (SD)58.3 (8.0)57.9 (7.4)53.7 (9.8)52.1 (11.5)50.9 (8.6)53.2 (9.6)
Sex, n (%) female14 (93.3)6 (75.0)6 (60.0)10 (83.3)10 (83.3)32 (76.2)
Years since onset of
symptoms, mean (min,
max)
11.5 (1.1, 39.8)13.1 (1.6, 29.5)11.7 (4.0, 20.8)15.0 (2.5, 50.0)10.4 (1.8, 23.2)12.5 (1.6, 50.0)
Years since diagnosis, mean
(min, max)
11.1 (1.1, 39.8)12.8 (1.6, 28.5)9.3 (2.2, 19.9)12.6 (0.5, 44.0)8.5 (1.2, 23.2)10.7 (0.5, 44.0)
Baseline disease activity
DAS28-CRP, mean (SD)5.7 (1.18)5.4 (0.85)5.0 (0.98)5.5 (0.56)5.0 (0.58)5.2 (0.76)
Patient global assessment, mean (SD)64.3 (28.6)47.5 (15.9)52.2 (19.5)61.9 (17.2)59.9 (16.8)56.3 (17.7)
Physician global assessment, mean (SD)64.1 (21.1)57.9 (17.8)54.6 (12.5)66.0 (12.0)59.8 (11.7)60.0 (13.5)
CDAI39.8 (13.0)39.3 (11.9)29.3 (9.4)37.7 (7.3)30.1 (5.6)33.8 (9.3)
Swollen joints10.0 (4.2)9.5 (5.3)7.1 (2.5)8.8 (2.7)6.6 (1.0)7.9 (3.1)
Tender joints16.9 (7.1)19.3 (7.4)11.5 (4.9)16.2 (5.2)11.5 (5.7)14.3 (6.4)
CRP (mg/liter)19.1 (34.3)4.7 (5.5)9.2 (10.4)7.7 (6.1)8.5 (12.8)7.7 (9.2)
ESR (mm/hour)39.0 (25.6)27.0 (15.4)29.1 (19.9)35.3 (17.3)37.8 (25.7)33.0 (20.1)
RF (U/ml)255 (292.0)505 (670.5)394 (752.9)187 (199.0)242 (207.9)312 (488.2)
RF positive, n (%)13 (86.7%)7 (87.5%)7 (70.0%)10 (83.3%)11 (91.7%)35 (83.3%)
ACPA positive, n (%)15 (100%)6 (75%)10 (100%)12 (100%)12 (100%)40 (95.2%)
DMARDs14 (93.3%)8 (100%)10 (100%)11 (91.7%)11 (91.7%)40 (95.2%)
Corticosteroids5 (33.3%)3 (37.5%)2 (20.0%)5 (41.7%)3 (25.0%)13 (31.0%)